Compare HQI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | IFRX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | Germany |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 225.5M |
| IPO Year | 2008 | 2017 |
| Metric | HQI | IFRX |
|---|---|---|
| Price | $13.48 | $1.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $20.50 | $8.29 |
| AVG Volume (30 Days) | 39.9K | ★ 1.1M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $4.19 | N/A |
| P/E Ratio | $31.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $0.80 |
| 52 Week High | $20.84 | $2.95 |
| Indicator | HQI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 27.04 |
| Support Level | $12.20 | $0.81 |
| Resistance Level | $18.65 | $1.07 |
| Average True Range (ATR) | 1.36 | 0.15 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 21.76 | 0.00 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.